CN1213768C - Method of treating endotoxemia - Google Patents

Method of treating endotoxemia Download PDF

Info

Publication number
CN1213768C
CN1213768C CNB998079499A CN99807949A CN1213768C CN 1213768 C CN1213768 C CN 1213768C CN B998079499 A CNB998079499 A CN B998079499A CN 99807949 A CN99807949 A CN 99807949A CN 1213768 C CN1213768 C CN 1213768C
Authority
CN
China
Prior art keywords
lps
gene
cell
cdna
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998079499A
Other languages
Chinese (zh)
Other versions
CN1307487A (en
Inventor
彼得·M·C·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of CN1307487A publication Critical patent/CN1307487A/en
Application granted granted Critical
Publication of CN1213768C publication Critical patent/CN1213768C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/05Triphosphoric monoester hydrolases (3.1.5)
    • C12Y301/05001Triphosphoric monoester hydrolases (3.1.5) dGTPase (3.1.5.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Abstract

The invention provides a therapeutic agent comprising an Lps<d> gene, which downregulates the transduction of LPS-mediated signals and can therefore be administered in order to treat or prevent the occurrence of endotoxemia.

Description

The method of treatment endotoxemia
The cross reference of related application
The application requires the priority of No. 60/083,210, the U.S. Provisional Application submitted on April 27th, 1998.
Government concerned subsidizes
The present invention described here provides part to subsidize by the appropriation that national sanitary office (NIH) is numbered 1RO1AI39159-01A1 and 1RO1CA70854-01.Federal government has specific right to this invention.
Invention field
The present invention relates to Lps dThe application of gene in treatment and prevention endotoxemia.
Background of invention
A)LPS
LPS is the macromole of a complexity, and from the cell wall of some antibacterial, wherein the part antibacterial can cause diseases such as enteric fever, dysentery, urinary tract infection, and other antibacterial is generally the bacterial parasite of animal and human's intestinal but is generally not pathogenic.All these antibacterials all have the cell wall of same type, and range gram negative bacteria according to their dyeing property.
The generation and the release of other medium of the LPS induction of immunity competent cell factor and animal inflammatory response.Cytokine is the very highly active a kind of material that has by various cells generations, these cells such as mononuclear phagocyte and lymphocyte, and they stimulate other cell and stimulate mutually.Endotheliocyte and granulocyte also are endotoxic primary target cells.Now special receptor molecule in the animal body inner cell and signal transduction path are carried out deep research, be well understood to the endotoxic mechanism of action.
B) hereditism of LPS responsiveness
By further investigation, it is found that endotoxic cell response is subjected to genetic control to mice.Nineteen sixty-eight to the discovery of C3H/HeJ mutant mice clear and definite first the host to the hereditism basis of the multiple reaction of LPS (Sultzer etc., nature, 219,1253-1254 (1968)).This Mus system is on the low side to the immunostimulation and the Pathophysiology effect responsiveness of lipid A component among the LPS, and therefore thinks, the responsiveness Mus system very near with sibship compares, and it has a kind of basic defective to the reaction of LPS.
The C3H/HeJ defective is special, and shows as multiple mode.For example, behind the B cells contacting LPS of C3H/HeJ, propagation or differentiation do not take place, their thymocyte cell is not strengthened by LPS by the inductive propagation of concanavalin A.(Sultzer etc., natural neontology (Nature New Biology) (London) 240,198-200 (1972); Sultzer, summary (Abst.Am.Soc.Microbio1.) 85 pages of AAM, M69 (1973); Tanabe etc., microbial immunology (Microbiol.Immuno.) 23,1097-1104 (1979); Morrison etc., immunology progress (Adv.Immunol.) 28,294-312 (1979); Sultzer, " endotoxic useful influence " 11 chapters, Plenum, NY (1983); Sultzer etc., immunobiology (Immunobiology) 187,257-271 (1993); Glode etc., L.M. and D.L.Resenstreich, Journal of Immunology (J.Immunol) 117,2061,2068 (1976); Sultzer, B.M. infect and immunity (Infection and Immunity) 13,1579-1584 (1976).The phagocytosis of macrophage and cytotoxicity are not to be stimulated by LPS, and in reacting cells the LPS institute stimulated cells factor, do not induced in the macrophage of C3H/HeJ as tumor necrosis factor (TNF), interferon (IFN), colony stimulating factor (CSF), interleukin 1 (IL-1) and prostaglandin.(Morrison etc., immunology progress 28,294-312 (1979)).In addition, compare with normal endotoxin responsiveness mice, C3H/HeJ has very strong resistance (Sultzer, nature 219,1253-1254 (1968)) to the lethal endotoxin shock.
It is not because of lacking accessory cell, existence inhibition cell or LPS combine not enough (Sultzer, " endotoxic useful influence " 11 chapters, Plenum, the NY (1983)) with other immunologically competent cell that the C3H/HeJ cell is not replied LPS.More properly, the explanation that is provided concentrates on: cell and LPS begin to do the time spent, and problem (Sultzer etc., immunobiology 187,257-271 (1993)) has appearred in the somewhere that lacks a key receptor or signal transduction path.
With C3H/HeJ Mus system and various reaction Mus is that the classics that carry out are fed the experimental result demonstration, to mitogenetic several codominant allele controls (Morrison etc., immunology progress, 28, the 294-312 (1979) that is subjected to single site that reply of LPS; Sultzer, " endotoxic useful influence " 11 chapters, Plenum, NY (1983); Sultzer etc., immunobiology 187,257-271 (1993); Glode etc., Journal of Immunology 117,2061-2068 (1976); Sultzer infects and immunity 13,1579-1584 (1976)).Watson thinks this gene loci (Lps n) be positioned at chromosome No. 4, link to each other with the proteic gene loci of main urinary system (Mup-1), at the Lyb2 of Mup-1 gene and control B cell activation: the downstream of 2: 4: 6 genes (Watson etc., Journal of Immunology 120,422-429 (1979)).C3H/HeJ mouse contains the Lps of sudden change dAllele.
C) separation and qualitative Lps nGene
Sultzer etc. (immunobiology 187,257-271 (1993)) have described a cDNA library that comprises six word banks with the splenocyte preparation of C3H/OuJ mice (LPS is responded).Comprising 2 * 10 4Individual difference clone's a word bank imports the splenocyte of C3H/HeJ mouses (LPS is not had reaction), and the plaque forming cells who reacts with sheep red blood cell (SRBC) behind the adding LPS in culture medium has increased by four times.
Kang etc. (infect and immunity 64,4612-4617 (1996)) further functional screening and fractionated to C3H/OuJ cDNA library have been described, and a cDNA clone's separation, this clone can recover the B cell response of C3H/HeJ spleen B cell by the LPS mediation.The cDNA sequence of 1166 nucleotidess of this section (SEQ ID NO:1) comprises the open reading frame of 648 nucleotidess, Q 216 the amino acid whose protein (SEQ ID NO:2) of encoding.
Sequence analysis shows, this LPS responsiveness gene (Lps nGene) GTP enzyme Ran/TC4 (Raetz, C.R.H., endotoxin chemistry, biochemistry yearbook (Ann.Rev.Biochem.) 59,129-170 (1990) that the pair cell nuclear translocation is very important of coding; Watson etc., Journal of Immunology 114,1462-1468 (1975); Kabir etc. infect and immunity 15,156-164 (1977)).At amino acid levels, Lps nIdentical with the Ran/TC4 GTP enzyme of finding in people and the Canis familiaris L., with the Ju93 of chicken with zymic Spil albumen 98.6% and 82.8% homology (Drivas etc., Mol Cell Biol molecule and cytobiology, 10,1793-1798 (1990) are arranged respectively; Dupree etc., Gene gene 120,325-326 (1992); Trueb etc., FEBS 306,181-184 (1992); Matsumoto etc., Cell cell 66,347-360 (1991)).The conclusion of Kang, Drivas above this conclusion has made up, Dupree, Trueb, Marsumoto.At dna level, Lps nThe homology of gene is 89.7%, 90.7%, 85.4% and 68.7% in the Ju93 of the TC4/Ran of people's TC4/Ran, Canis familiaris L., chicken and zymic Spil successively.Therefore, Lps nMolecule is high conservative on evolving, 5 of this molecule domains especially, and G1-G5 has found that they are relevant with the combination and the hydrolysis of guanine nucleotides.
In a word, Lps nFunctioning gene product of gene code, this product appear in the B cell that produces polyclone activation antibody in the LPS responsiveness mice (as the C3H/HeOuJ mice), with Lps nCDNA imports C3H/HeJ B cell to be enough to recover the responsiveness that cell stimulates for LPS, thereby makes the plaque forming cells's (PFC) who produces antibody level be increased to the level of responder.It is believed that this gene does not exist only in the B cell, and be present in other cell that LPS is had responsiveness and produce in the cell of cytokine and other factors (these factor amounts can produce toxic action to the host when big).
D) endotoxemia
LPS has multiple pathophysiology effect, and one of them is exactly owing to existing a large amount of endotoxins to cause endotoxemia or septic shock in the blood, fatality rate about 40%.Most of septic shock case is the result who occurs gram negative bacteria in the blood.But septic shock also may be caused by other biological such as gram-positive bacterium and fungus.Yet, the broad research of the septic shock cause of disease is confirmed that a key factor that causes septic shock is that LPS discharges from gram negative bacteria, endotoxin exerts an influence to various cells in the body subsequently, they is become highly activate.As a result, too much cellular material is arranged in the host, this causes circulatory failure, shock and death.
Sepsis is the common cause of the death of intensive care unit(ICU), remains a serious public health problem at present.When sepsis took place, main preceding inflammatory cytokine comprised that TNF-α, IL-1 and IL-6 all have and relates to.With anti-TNF antibodies or suppress clinical test results unsatisfactory (Dellinger etc., breast (Chest) 111, the 744-753 (1997) of TNF by the fusion rotein that the Fc of TNF ectodomain and IgG partly forms; Grau etc., natural medical science (Nature Medicine) 3,1193-1195 (1997)).
Although can be with potent antibiotics and the depletion of Drug therapy cardiopulmonary, but still medicine that the utmost point need be improved and/or prophylactic treatment scheme control endotoxemia, especially controls in early days at sepsis.
The invention summary
The invention provides the method for treatment endotoxemia in this patient who needs is arranged, it comprises the Lps that gives effective dose dGene.Lps dGene is different from Lps nThe gene part is that it contains a sudden change, makes that the endotoxic responsibility of lipopolysaccharide reduces in the cell that contains this sudden change.In one embodiment of the invention, Lps dGene and corresponding Lps of the same race nThe difference of gene is, at Lps n3 ' the untranslated region of cDNA has a sudden change.In a preferred embodiment, this sudden change has a nucleotide subsitution 870 of described Lps DNA, and wherein said Position Number starts from the translation initiation codon of this DNA.In a preferred embodiment, Lps dGene is people's a gene.In another embodiment, Lps dGene is a musculus cdna.Because the identical albumen of Lps gene code of people and Mus is so musculus cdna may also can be used for the treatment of.In a more preferred, Lps dGene is with the form administration in the viral vector.In a most preferred embodiment, this viral vector is a retroviral vector.In another preferred embodiment, this viral vector is an adenovirus vector.
The present invention also provides the method for prevention endotoxemia in this patient who needs is arranged, and it comprises the Lps that gives effective dose dGene.In a preferred embodiment, this Lps dGene is with the form administration in the viral vector.In a most preferred embodiment, this viral vector is a retroviral vector.This viral vector is an adenovirus vector in another most preferred embodiment.
The present invention also comprises Lps dGene is used for the treatment of or prevents application in the medicine of endotoxemia in patient's body in preparation.
Other aspects and advantages of the present invention are all to scheme or the following detailed description of its preferred embodiment is described.
The accompanying drawing summary
Figure 1A-1D shows a Lps dThe difference clone's of cDNA DNA sequence.Top delegation is Lps nThe sequence of cDNA is separated from wild type LPS responsiveness C3H/HeOuJ mice.Lps d-4 ,-10 ,-15 and-17 are 4 is selected from the plasmid dna sequence that contains C3H/HeJ cDNA respectively.Numbering starts from the A (the 1st) of translation initiation site ATG, and it is represented with runic and underscore.All 4 clones' DNA all contains identical sudden change at 870, and promptly the T residue is replaced by the C residue.
Fig. 2 has shown that retroviral gene changes the flow chart of the elementary spleen B cell of C3H/HeJ mouse over to.
Fig. 3 A shows the N2 retroviral vector.Fig. 3 B shows N2-Lps nThe reverse transcription carrier.Fig. 3 C shows N2-Lps dThe reverse transcription carrier.
Fig. 4 A-4D shows stimulation and the retroviral metainfective MTT proliferation test that starts LPS.
Fig. 5 shows the RT-PCR test of the spleen B cell of retroviral infection.MM is a molecular weight standard.In 3 times or more times repeated experiments, obtained similar result.
Fig. 6 is presented at derived from normal inbred mouse (Ana I), LPS and hangs down in the macrophage system of responsiveness C3H/HeJ mouse (GG2EE), with infecting retrovirus N2-Lps (d) (#1, #7, #9 and P30) Ana I cell in, LPS is to the stimulation of TNF-alpha expression.
Fig. 7 A and 7B have shown Lps respectively nAnd Lps dThe secondary structure of 3 '-untranslated region among the mRNA.870 is single base substitution site, by T (Lps n) be replaced into C (Lps d).
Fig. 8 illustrates the Ad5-Lps construction of recombinant adenovirus containing.Black surround is the necessary viral ITR of viral dna replication (an oppositely terminal repeat)." Ψ " refers to packaging sequence, and CMV is a cytomegalovirus promoter.In construct, the E1 district of Ad5 is by Lps nCDNA (1.1kb), Lps dCDNA (1.1kb) or green fluorescent protein (GFP) gene (0.8kb) displacement.
Fig. 9 is Lps d, Lps nOr green fluorescent protein (GFP) cDNA is transferred to endotoxin resistance figure behind the responsive mice of LPS by adenovirus vector.Every mice is accepted 1mg LD 100Endotoxin, after 1 hour, the various adenoviruss of intravenous injection contain 10 10The culture supernatant of individual infectious viral particle.Then along with the time observes animal.(open loop) animal of dead (closed loop) and work is record as shown.
Figure 10 is presented at different time points, has infected Ad5-Lps dOr Ad5-Lps nThe peripheral blood lymphocytes of mice in the expression of adenoviral gene.With embodiment 6 described Auele Specific Primers total RNA extract of peripheral blood lymphocytes is carried out nested type RT-PCR amplification.The expection size of amplified production is 793bp.
Detailed Description Of The Invention
A) definition and total methodology
Be intended to help to understand scope of the present invention and practice to give a definition.
" LPS " refers to the lipopolysaccharides endotoxin.
“Lps n" and " Lpsd" be used to describe normal (responsiveness that refers to LPS) and low responsiveness fat The separately equipotential form of polysaccharide endotoxin response gene (no matter the species in source). LpsdComprise coding LPS Albumen, but its gene comprises a sudden change, makes the cell that contains this class sudden change react low appointing to LPS What gene. LpsnGene also claims Ran/TC4 or TC4/Ran. Term " Lps gene " comprises LpsnAnd Lpsd, and the natural and LPS endotoxin response gene laboratory generation of other form.
" Lps nAlbumen " and " Lps dAlbumen " be used to describe Lps respectively nAnd Lps dThe polypeptide of gene code.Term " Lps albumen " comprises Lps nAlbumen and Lps dAlbumen, and the natural and LPS endotoxin response gene product laboratory generation of other form.
According to one embodiment of the invention, Lps dGene is different from the corresponding Lps of identical biology nThe gene part is that the 3 ' untranslated region of its mRNA (3 ' UTR) has a sudden change.This sudden change makes that difference appears in the secondary structure of mRNA in the saltation zone.In a more preferred, this sports a single point sudden change, as the T-C sudden change on C3H/HeJ mouse Lps cDNA 870 (the site numbering starts from translation initiation codon ATG).
In a word, be in the field known and commonly used about the name and the laboratory method of cell culture, molecular genetics, nucleic acid chemistry and hybridization hereinafter.The standard technique that the present invention has used that recombinant nucleic acid, polynucleotide are synthetic, cell culture and transgenic insert.Enzyme reaction, oligonucleotide synthesize and purification step is mostly undertaken by producer's explanation.Used technology and method are mostly carried out according to the various general document that the conventional method and the technical staff of this area knows, these documents comprise Maniatis (molecular cloning, cold spring harbor laboratory, 1982) and Ausubel (the up-to-date experimental technique of molecular biology (Current Protocols inMolecular Biology), Wiley and sons, 1987), they all are incorporated herein by reference.
B) carrier and gene transport method
The Lps of people and Mus nAlbumen has identical aminoacid sequence, the Lps of people and Mus on dna level n(TC4/Ran) gene shows 89.7% homology.Can therefore use side-directed mutagenesis, or with people Lps nGene with contain mice Lps dThe restriction fragment of sudden change makes up and the people Lps of generation sudden change dGene (cDNA).In one embodiment, this sudden change is the distinctive Lps of C3H/HeJ mouse n870 T in the gene cDNA → C sudden change.People's Lps dGene can be used as gene therapeutic agents downward modulation to the replying of LPS, and therefore is used for the treatment of or prevent the generation of the interior endotoxemia of patient's body.Perhaps, because the Lps albumen of people and Mus is identical, Mus Lps dGene can be used as human gene therapy's ordered sequence.
Lps nThe sudden change that causes the LPS responsiveness to reduce in the gene can followingly be induced: use known induced-mutation technique, the mutant that required LPS responsiveness is arranged that is aided with producing screens.Make Lps nThe cDNA sudden change is cloned into respective carrier such as N2 retroviral vector (Wong etc., molecular cytobiology 9,798-808 (1989); Wong etc., Genes Dev.1,358-365 (1987)), this carrier contains 5 ' and 3 ' MMLV LTR, donor splicing site and acceptor splicing site and a neomycin resistance marker gene.Use gained pN2-Lps xPlasmid DNA transfection has been packed viral cell, obtains viral supernatant from this class cell.Precipitate virion with known technology.Use N2-Lps xCarrier infects macrophage, as the Ana I macrophage system derived from normal inbred mouse.Analyze the generation of cell TNF α after LPS stimulates of transduction.
The downward modulation of the signal transmission of LPS mediation is measured by the minimizing that TNF α in the maximum phase place control cells of not transduction produces in the transducer cell.Selection is induced the sudden change cDNA of LPS responsiveness downward modulation by importing macrophage.With Lps xGene is set forth in following examples by the representative art that retrovirus is transported to the target effector lymphocyte.
Preferably, can cause the Lps that the LPS responsiveness reduces nThe sudden change of gene can significantly reduce, but can thoroughly not eliminate the LPS responsiveness of host cell.
Lps dGene preferably imports in patient's body with the form of viral vector.Can be used for viral vector of the present invention and comprise adenovirus vector and retroviral vector.
Adenovirus is an eukaryotic cell dna virus, can be modified and nucleic acid is changed in various types of cells effectively.Adenovirus has various serotypes, comprises 2 types and 5 type adenovirus hominiss and animal adenovirus.Preferred replication defective sexual gland virus carrier of the present invention comprises sequence and purpose nucleic acid in ITR, a kind of shell.More preferably, the no function in E1 district of adenovirus vector at least.Other district may also be modified, comprises E3 district (seeing WO 95/02697), E2 district (seeing WO 94/28938), E4 district (seeing WO 94/28152, WO 94/12649 and WO 95/02697), or among the late gene L1-L5 any.
Replication defective recombinant adenoviral vector of the present invention can prepare with technology well known by persons skilled in the art.Specifically be that available adenovirus prepares with the homologous recombination of the plasmid that carries the target DNA sequence.Adenovirus and plasmid co-transfection to corresponding cell line can be carried out effective homologous recombination.Used cell line should be able to transform with described component, and comprises the sequence of the defect area that can remedy this replication defective sexual gland virus.Available cell line example comprises that the person embryo cell is 293 (Graham etc., general virology magazine (J.Gen.Virol.) 36,59 (1977)), be integrated with the left end sequence (account for this virus genomic 12%) of Ad5 adenoviral gene group in its genome, with the cell line of the function that can remedy E1 district and E4, as described in WO 94/26914 and WO 95/02697.Reclaim recombinant adenovirus, with the standard biological well known to those skilled in the art purification that learns a skill.
General preferred adenovirus vector is used for the treatment of endotoxemia, wherein effectively treatment should usually occur in 24 hours.The adenovirus vector that can produce high titre is (as 10 10-10 12And can be infectious unit/milliliter), with the not responsiveness phenotype of non-tissue specificity mode transient expression LPS.
Retrovirus is to integrate virus, the cell that common infection is being broken up.The reverse transcription virus gene group comprises sequence and three coding regions (gag, pol and env) in two LTR, the shell.Construction of recombinant defective retroviral vector is that those skilled in the art are known.
In the recombinant retroviral vector, gag, all or part of usually disappearance of pol and env gene replaces the purpose nucleotide sequence of external source.These carriers can be from dissimilar retroviral constructs, as M-MuLV, MSV (mice Moloney sarcoma virus), HaSV (Harvey sarcoma virus), SNV (spleen necrosis virus), RSV (Rous sarcoma virus) and Friend virus.
Usually, in order to make up the recombinant retrovirus that comprises sequence of the present invention, need to make up a plasmid, it comprises sequence and coded sequence in LTR, the shell.Package cell line with retroviral functional defect in the trans additional plasmid of energy of this construct transfection.Usually, therefore this package cell line can express gag, pol and env gene.This class package cell line is described in the prior art.Specifically can mention cell line PA317 (US 4,861,719), PsiCRIP cell line (WO 90/02806) and GP+envAm-12 cell line (WO 89/07150).The recombinant retroviral carrier can be with standard technique purification well known by persons skilled in the art.
Availablely in Unseparated Cell, transport material derived from retroviral vector such as slow viruss such as HIV-1, HIV-2 and SIV.These viruses can have other virus, as the surface glycoprotein of M-MuLV or VSV (vesicular stomatitis virus), thereby have false phenotype.Bartz and Vodicka have described the preparation (method (Methods) 12 (4) of the high titre HIV-1 that has the false phenotype of VSV glycoprotein; 337-42 (1997, August)), Zufferey etc. have described repeatedly the slow virus carrier of attenuation (Nature Biotechnol 15:871-75 (1997, JIUYUE)).This class slow virus carrier can infect Unseparated Cell, and the broad host range is arranged, and can concentrate paramount titre by ultracentrifugation.
Chimeric adenoviral/retroviral vector system also can be used for carrying out effective gene transmission and long-term gene expression.People such as Feng have described a kind of embedded virus system, wherein produce survivor's cell with generating instantaneous retrovirus in the adenovirus vector body, so that the filial generation retroviral particle infects adjacent cells (Nature Biotechnol 15:866-70 (1997, JIUYUE)).
Retroviral vector is preferred for preventing the intravital endotoxemia of endotoxemia high-risk patient.As, the fire victim is 100% generation endotoxemia almost.Because retroviral vector can be integrated into hematopoietic stem cell, thereby they can generate the warehouse of LPS resistance T cell, B cell and macrophage.
Recombinant viral vector all gives the patient with treatment or prevention endotoxemia with effective dose.Effective dose depends on the type of patient characteristics, the pending patient's condition and seriousness, expection course of treatment, medication and other factor.Effective dose can be by doctor or other experienced medical expert's decisions.Recombinant viral vector of the present invention is generally with every dose 10 4-10 14Form preparation and the administration of pfu.
Embodiment
Practice of the present invention illustrates through following examples.These embodiment are only for illustrating scope of the present invention, and unrestricted.
Embodiment 1
C3H/HeJ mouse Lps dThe separation of gene and evaluation
The research of Kang etc. (infecting and immunity, 64,4612-4617 (1996)) shows Lps nGene can recover the B cell response of lipopolysaccharide mediate in the C3H/HeJ mouse spleen B cell.
For Lps gene in the confirmation C3H/HeJ mouse genome is a defective, and this defective has caused the low responsiveness to the LPS stimulation, separation Lps gene from the cDNA library of pCD-HeJ.
RNA with C3H/HeJ spleen B cell makes up Okayama-Berg cDNA expression library (Okayama, H. and Berg, P. etc., molecular cytobiology (Mol.Cell Biol.), 2,161-170 (1982)).8 flat boards are coated (on every 150mm flat board 5.8 * 10 in pCD-HeJ cDNA library 4Individual clone), use the Lps of LPS responder mice C3H/HeOuJ nThe BamHI-PstI fragment of 0.9kb is surveyed this library (infecting and immunity, 64,4612-4617 (1996)) among the cDNA.25 positive colonies have been identified.
In 25 independent clonings being analyzed, 8 is full-length cDNA, as with C3H/HeOuJ (wild type) Lps nThe size of cDNA is more determined.Again to 4 full length cDNA clone (Lps independently wherein d-4 ,-10 ,-15 and-17) check order.Sequence and wild type Lps with these 4 independent cloning nCDNA compares.
These 4 clone's all are presented at Lps nThe 870th of cDNA identical point sudden change (the residue numbering starts from ATG) has taken place, and promptly the T residue is replaced by the C residue, shown in Figure 1A-1D.What is interesting is that this simple point mutation occurs in 3 ' untranslated region.By Northern (RNA) engram analysis, C3H/HeJ and C3H/HeOuJ cell do not have significant difference on Lps mRNA level.
These data show, occur in the HeJ Lps of sudden change dPoint mutation on the gene is to cause the reason of C3H/HeJ cell to the low responsiveness of LPS.
Utilize the SQUIGGLES program of GCG sequence analysis software bag (Wisconsin) to compare Lps nAnd Lps dThe secondary structure of mRNA.Fig. 7 A (Lps n) and Fig. 7 B (Lps d) be presented at point mutation proximity RNA secondary structure gross differences is arranged, then there is not significant architectural difference in the zone of point of distance sudden change.Occur in Lps dThe single base in 3 ' the UTR zone of mRNA replaces prompting, has the mRNA domain of a uniqueness, its can by modulin in conjunction with and implement transcribe the back and regulate, influence translation efficiency, or influence mRNA stability, transport or born of the same parents are interior locatees.For the further product of identifying Lps gene wild and sudden change, and the effect in LPS replys, made up Lps nAnd Lps dRetroviral vector.
Embodiment 2
Lps nAnd Lps dExpressed by Retrovirus Vector
Lps with embodiment 1 nAnd Lps dCDNA is cloned into XhoI site (Wong etc., molecular cytobiology, 9, the 798-808 (1989) of N2 retroviral vector; Wong etc., Genes Dev.1,358-365 (1987)).This N2 retroviral vector comprises 5 ' and 3 ' MMLV LTR, donor splicing site and acceptor splicing site, and a neomycin resistance marker gene.
With Lps nCNDA separates (infecting and immunity, 64,4612-4617 (1996)) and is connected on the site of XhoI restriction fragment of N2 retroviral vector from the XhoI restriction fragment of pCD-LPS, produces pN2-Lps nMaking uses the same method produces pN2-Lps dCarrier, that different is used LPS for sudden change dCDNA.
Carry Lps in order to produce nAnd Lps dThe retrovirus reserve of sequence is used pN2-Lps respectively nAnd pN2-Lps dPlasmid DNA is with calcium phosphate DNA coprecipitation transfection GP/E virus incasing cells (Markowitz, etc., Journal of Virology, 62,1120-1124, (1988)).The positive transfectant of screening on the culture medium that contains 1mg/ml G418.Single G418 resistance clone obtains separating, increasing bacterium and evaluation.
In order to produce spissated viral supernatant, from the cell that produces virus, collect virus, and with 600 μ, 1 viral supernatant in the PEG 8000 of 0.4M NaCl and 8.5% (Sigma) in 4 ℃ of continuous stirring 1-1.5 hours so that virus precipitate.Centrifugal 10 minutes of 7500rpm is with collecting precipitation.Precipitation is dissolved with the NTE buffer (100mM NaCl, 10mM Tris-Cl pH7.4,1mM EDTA, filtration sterilization) of original volume 1%.Then this solution is splined on Sepharose CL-4B chromatographic column in 4 ℃.Collection also gathers a plurality of fraction.Each gather fraction after filtration degerming and with NIH/3T3 raji cell assay Raji G418 resistance with reflection virus titer (Wong etc., molecular cytobiology, 9,798-808 (1989)).
N2 parental generation carrier, N2-Lps nAnd N2-Lps dThe structure of carrier is shown in Fig. 3 A-3C respectively.
Embodiment 3
Lps nAnd Lps dGene changes in the spleen B cell of C3H/HeJ mouse through retrovirus
A) transfer of reverse transcription virus gene
Take from the spleen B cell of C3H/HeJ mouse, remove erythrocyte, in the presence of 100 μ g/ml LPS, carry out retroviral infection, in S17 Interstitial cell conditioned medium (known can stimulate pre-B cell growth), cultivate (Collins etc. then, Journal of Immunology, 138,1082-1087 (1987); Dorshkind etc., immunological method magazine (J.Immunol.Meathods), 123,93-101 (1989); Narendran etc., European Journal of Immunology (Eur.J.Immunol.), 22,1001-1006 (1992)).In order to make retroviral efficiency of infection the highest, upgrade culture fluid with the fresh stock solution of spissated viral supernatant repeatedly, as described in the flow chart of Fig. 2.N2 parental generation carrier, N2-Lps nOr N2-Lps dThe virus titer of the concentrated stock solution of carrier all is standardized as 2 * 10 6G418 bacterium colony/ml.
B) MTT proliferation test
After starting the stimulation and retroviral infection of LPS,, carry out MTT[3-(4 at the different time points collecting cell, 5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide] proliferation test (Han etc., NAS's journal 92,11014-11018 (1995)).
The cell culture flat board of a 100mm contains 10ml S17CM (cultivating the S17 cell 24 hours in the RPMI that contains 10% hyclone and 5uM 2 mercapto ethanol, the alignment at 0,12,24,48 hour), with 10 7The individual C3H/HeJ splenocyte that has removed erythrocyte places this flat board to cultivate 6 hours.Collect not adherent cell then, and infect mixture with 10ml and on a 100mm flat board, infected again 16 hours.This infection mixture contains the spissated viral supernatant of 3ml, and (titre is 2 * 10 6Individual virion/ml), 1ml S17CM, 10 μ g/ml polybrene, the Salmonella typhimurium LPS of the hot phenol extraction of 10-100 μ g/ml.After 16 hours, collecting cell, the infection mixture that reuse is fresh infected 16 hours.Then, stimulate the cell of collecting with 10 μ g/ml among the 2ml S17CM or 100 μ g/ml LPS, and on 24 orifice plates, cultivated 0,12,24,48 hours.Then, will be subjected to retroviral infection and LPS stimulated cells gets 100 μ l and places on 96 orifice plates.Add 10 μ l 5mg/ml MTT and and mixing with cells, then this flat board is placed incubator.Cultivate after 4 hours, add the isopropyl alcohol that 100 μ l contain 0.04NHCl, fully mix, on microdroplet plate readout instrument, read the O.D. at 570nm place.
32 hours (be shown in Figure 2 cultivation 0 hour), do not find the significant difference (Fig. 4 A) of cell proliferation between all cultures.At 44 hours (be shown in Figure 2 cultivation 12 hours), N2-Lps nInfection cell shows tangible cell proliferation, and N2-Lps dCell or N2 infection cell then do not have (Fig. 4 B).The infection of culture starts after 68 hours (be shown in Figure 2 cultivation 48 hours), N2-Lps nInfect culture and N2 and infect culture or N2-Lps dInfect between the culture, in LPS replys, have 4 times maximum differential.This is replied from 92 hours and begins to reduce.
In cultivation, N2-Lps nThe C3H/HeJ spleen B cell that infects is replied at 44 hours viewed LPS, accepts the LPS of LPS stimulation after 24 hours with C3H/HeOuJ responder spleen B cell and replys level identical (not video data).After this delay was attributable to (1) 48 hour, 50% the cell of only having an appointment was by N2-Lps nCarrier transduction, the integration of (2) virus and the expression of transducible gene need a lag time.N2-Lps nThe culture that infects is than N2 or N2-Lps dThe cell proliferation of the culture that infects is more obvious, because small lymphocyte that the former is breeding and blastogenic cell number are all far above the latter (data are unlisted).And, the differentiation of polyclone B cell has also taken place, because N2-Lps nThe C3H/HeJ spleen B cell of transduction can be stimulated by LPS and produce the antibody of cracking sheep red blood cell (SRBC), similar (Kang etc., infection and immune, 64,4612-4617, (1996)) that this report with past attempts, but N2 or N2-Lps dThe C3H/HeJ spleen B cell of carrier transduction then can not.
C) RT-PCR analyzes
In order to further specify, to LPS to reply or do not reply be because corresponding wild type or saltant Ran cDNA successfully shift through retroviral, the cell of all cultures is carried out RT-PCR analyzes.Wherein use specificity 5 ' the oligomerization primer of the SV40 promoter that occurs in the retroviral vector and be specific to Lps nOr Lps d3 ' the primer of cDNA.
From the spleen B cell of retroviral infection, extract total RNA with 4M GTC and phenol/chloroform.Produce cDNA with AWV-RT.The PCR reaction has two primers: 5 ' primer (TCTAAAAGCTGCTGCAGG, SEQ ID NO:3) is from the XhoI fragment of pCD, and 3 ' primer (GTACACGATCTGCTTAGC, SEQ ID NO:4) from Lps cDNA, is used to produce the fragment of a 907bp.The result as shown in Figure 5.
N2-Lps nAnd N2-Lps dThe 907bp band that as seen cell of being transduceed all expects, the cell that N2 virus is transduceed does not then have, the gene successful expression of this proof transduction.This primer specific is in LpsRNA, because when carrying out the PCR reaction with genomic DNA, do not see 907bp band shown in Figure 5.This is in the carrier sequence of Lps cDNA upstream because of 5 ' primer specific.So Lps in the C3H/HeJ mouse spleen B cell nCDNA but not Lps dThe importing of cDNA and expression have caused the recovery to the remarkable responsibility of LPS stimulation.The classical multiply test of C3H/HeJ system and other responder strain mice shows that the mitogenesis of LPS is replied the single site that is subjected to by codominant allele is formed and controlled.Clearly show that in this result displayed Ran is the Lps response gene, it is a defective in the C3H/HeJ mouse of LPS being replied reduction.
Embodiment 4
Lps dGene is transferred in the macrophage of normal inbred mouse through retrovirus
Ana I is the macrophage system from normal inbred mouse, and GG2EE is the macrophage system from C3H/HeJ low responder mice.N2-Lps (d) retroviral vector with embodiment 2 infects Ana I cell, and analyzes the generation that the cell of transduceing is subjected to the TNF α of LPS stimulation back different time points.
During the retrovirus transduction, make 1 * 10 6The suspension of individual cell mixes when having 10 μ g/ml polybrene to exist with 5 milliliters of retrovirus supernatants.In 37 ℃, 5%CO 2Middle shaken cultivation 4 hours.Make cell then centrifugal 10 minutes, use D in 1500rpm 10G (DMEM adds 10% heat-inactivated FBS, 2mM L-glutaminate, 10 μ g/ml gentamycins and 1mg/ml G418) washes and is resuspended in 5ml D 10Among the G.1.6ml methylcellulose, the cell of 0.4ml retrovirus transduction, 1mg/ml G418 are mixed with preparation methylcellulose mixture, and (the about 1.1ml of every flat board) is taped against on the 35mm flat board with this mixture.Picking colony increases bacterium, the back collection of two weeks.
Carry out LPS when stimulating, cell (Ana I, GG2EE, and the Ana I cell of retrovirus transduction) is seeded on the plate in 24 holes (5 * 10 5Individual cells/well), in 37 ℃ of 5%CO 2The middle cultivation.0,24, use the LPS irritation cell of 100ng/ml in the time of 48 or 72 hours respectively.Collect culture supernatant, measure the amount of TNF α with the ELISA method.
Be TNF α and analyze, every hole adds the TNF α capture antibody (2 μ g/ml) of 50 μ l on the microdroplet plate, and 4 ℃ are spent the night.Flat board is washed 4 times with PBST then, and every hole adds confining liquid (200 μ l), room temperature 30 minutes.Dull and stereotyped reuse PBST washes 4 times, and every hole adds sample 100 μ l.4 ℃ are spent the night, and then wash 4 times with PBST.In order to detect TNF α, every hole adds biotinylated TNF Alpha antibodies (1 μ g/ml, 100 μ l/ holes), and the plate room temperature was placed 1 hour, washes with PBST then.Add streptoavidin-HRP conjugate enzyme (dilution in 1: 1000,100 μ l/ holes), the plate room temperature was placed 30 minutes, wash 8 times with PBST.Add ABTS substrate (100 μ l/ hole), in room temperature, develop the color.By reading OD 405nm pH-value determination pH color.The result as shown in Figure 6.
#1, #7 and #9 independently clone, and P30 is the deutero-cell of mixture from 30 independent clonings.This experiment shows, Lps dThe expression of gene in Ana I responder cell can be reduced the signal transmission of LPS mediation in these cells.Lps dTherefore gene can do the generation that endotoxemia in patient's body was treated or prevented to the DNA medicine.
Embodiment 5
The preparation of the virus that construction of recombinant adenovirus containing and being used for shifts in the adenopathy toxicity Lps body
With Lps d, Lps nAnd the GFP gene is cloned on the Ad5 adenovirus vector as follows and is replaced its E1 district.The structure of carrier is by flow process shown in Figure 8.
With BamHI from pCD-Lps nAnd pCD-Lps d3249 and 35 downcut Lps nAnd Lps dCDNA (latter is contained the T-C sudden change 870 of cDNA, and it is provided by StemCell Therapeutics).Respectively they are inserted into the genomic E1 of Ad5 district, and are subjected to the CMV promoters driven.The GFP of pEGFP plasmid (green fluorescent protein) gene cuts out with BamHI and NotI, is inserted into same loci, and is subjected to the CMV promoters driven equally.Recombinant adenovirus is a replication defect type because of disappearance E1.But they can duplicate in containing 293 cells of E1 gene.In order to prepare recombinant virus, with reorganization Ad5DNA rotaring redyeing 293 cell.After 10 days, get and collecting cell by from culture bottle, scraping.The process freezing through ethanol/the dry ice bath of three-wheel and 37 degree thaw is fast got 293 cells on 20 150mm flat boards of 1ml employing virus cracking liquid infection.After three days, as above-mentioned collection virus, with CsCl with its centrifugal be banded with purification and to PBS dialysis three times.For measuring virus titer, inoculation 293 cells on 6 hole flat boards.After 24 hours, with the virus stock solution used infection of serial dilution.After two hours, remove culture medium, cell is covered on the culture medium that contains 2%PBS and 1% agarose, after 10 days, the plaque number on the counting flat board.The adenovirus vector titre is 10 12Pfu/ml.
Embodiment 6
Shift in the body that Lps carries out with adenovirus vector
In this research, outbreeding system CD1 mice is bought the company from Charles River, makes it get septic shock through inducing, then with having Lps d, Lps nOr the vehicle treated of GFP cDNA.Using outbreeding system CD1 mice is for the heterogeneous degree among the observation experiment result.
A) inoculation
With the endotoxic LD of mouse assay 50And LD 100Be respectively 0.6mg and 1mg.Every the interior inoculation of mouse peritoneum 1mg endotoxin (is equivalent to LD then 100).After 1 hour, every mouse mainline 10 10The Ad5-Lps of pfu/ml d, Ad5-Lps nOr Ad5-GFP virus 0.5ml.
B) survival
Observed mice every 6-12 hour.The result as shown in Figure 9.The useful 1mg LPS mice of handling dead in 36 hours, use Ad5-Lps nOr the mice that Ad5-GFP handles is also like this.Use Ad5-Lps dThe mice of handling has half dead in the same time period, but second half survival (Fig. 9).The heterogeneity of gene transfer treatment back survival is relevant with the use of outbreeding system mice.A survival Mus in this group shows dispiritedly when beginning, but it is very healthy then to become after the rehabilitation.The mice of only injecting Ad5 virus does not all have death, illustrates that it does not have toxicity.Therefore, the Lps of sudden change nThe transfer of cDNA can be saved the mice of endotoxin sensitivity is suffered a shock in deteriorated blood.
C) PCR of transduce mouse detects
For the existence of determining that adenoviral gene shifts, at different time collection Ad5-Lps dOr Ad5-Lps nCarried out the peripheral blood mononuclear cell of the mice of vivo gene transfer, to extract RNA, as described below.
The CD1 mouse tail vein inoculates about 10 10The infections recombinant adenoviruses granule of pfu.2,4, after 6,10 and 24 hours with whole blood collection in haematocrit.Centrifugal, collect faint yellow leukocytic cream, cracking in the GTC buffer (Wong etc., Journal of Virology, 68,5523-5531,1994) is to extract total RNA.The final volume of every part of RNA sample is 10 μ l; These samples all use the oligo-dT primer as described (the same) carry out reverse transcription.The cumulative volume of RT reaction is 20 μ l.Be used for as (the same) of once reporting, carrying out the nested PCR amplification from taking out 2 μ l the 20 μ l.In each reaction, in the reaction volume of 50 μ l, use the Taq polymerase (Sigma) of 1.5 units.The first round is during pcr amplification, and sample is earlier through 95 ℃ of degeneration in 5 minutes, then through degeneration (94 ℃ 1 minute), annealing (60 ℃ 1 minute) and primer extension (72 ℃ 1 minute) totally 20 circulations.Last takes turns 72 ℃ of primer extension of 10 minutes again.In the first round pcr amplification, 5 ' primer sequence (T7 positive-sense strand) is 5 '-TAA TAC GACTCA CTA TAG GGA GA-3 ' (SEQ ID NO:5), it is specific to the T7 promoter sequence, 3 ' primer sequence (D2 antisense strand) is 5 '-GAA ATT CAG AAA GGA AAC AAC TCT GTTCCA-3 ' (SEQ ID NO:6), and it is for being specific to the antisense sequences of Lps cDNA (starting from 810 nucleotide).Estimate that the dna fragmentation that is increased is 1020bp.Second takes turns in the nested PCR amplification, takes out 2 μ l and carry out second and take turns PCR from the reaction cumulative volume 50 μ l of first round pcr amplification.5 ' primer is pcDNA3 (Invitrogen) positive-sense strand sequence 5 ' ACT ATA GGG AGA CCC AAG CT-3 ' (SEQ ID NO:7), and it is specific to pcDNA3, and this carrier sequence is connected with Lps cDNA in the adenovirus vector when making up.3 ' primer (R1 antisense strand) sequence is 5 '-AGC AGT CGT CTGAGC AAC CT-3 ' (SEQ ID NO:8), and it is specific to Lps cDNA (starting from the 606th nucleotide).The product of estimating pcr amplification is 790bp.Sample is earlier through 95 ℃ of degeneration in 5 minutes, carry out then 94 ℃ 1 minute, a step 72 ℃ of primer extension reactions of 10 minutes are carried out in 60 ℃ of 1 minute and 72 ℃ of 35 circulations of 1 minute at last again.
D) PCR result
After the vivo gene transfer, only 2 hours cell RNA promptly comprises the band of a 793bp, has illustrated that there be (Figure 10) in retroviral mRNA.Do not see this band (Figure 10) when lacking reverse transcription or cDNA template.These data show the expression that adenoviral gene only just can take place behind the intravenous inoculation carrier in 2 hours.
The list of references of all references comprises disclosing and synthesizes that the document of preparation and analytical method all is hereby incorporated by.
The present invention also can be by other special scheme implementations, short of its spirit or basic feature, therefore, and when explanation scope of the present invention, except the description of reference front, more should be with reference to claims.
Sequence table
<110>Wong,Petex?M.C.
<120〉method of treatment endotoxemia
<130>252PC
<140〉application number is not arranged as yet
<141>1998-04-26
<150>60/083,210
<151>1998-04-27
<160>8
<170>PatentIn?Ver,2.0
<210>1
<211>1166
<212>DNA
<213〉mice
<400>1
cccccctccg?cgcgccggcg?tccgctgcgt?ctccggcatt?tgaatcgcgt?ccgccatctt 60
tccagctcca?gtcggacagg?cgcgcagact?cttctggaag?gatccgccgc?gacggccgcc 120
cagggagagc?cgcaggtcca?gttcaagctc?gtcctggtgg?gcgacggcgg?caccgggaag 180
acaaccttcg?tgaagcgcca?cttgacgggc?gagtttgaga?agaagtatgt?agccaccccg 240
ggcgtggagg?tgcacccgct?cgtcttccat?accaacagag?gacccatcaa?gttcaacgtg 300
tgggacacgg?ccggccagga?gaagttcggg?ggcctgcgcg?atggctacta?catccaagcc 360
cagtgtgcca?ttataatgtt?tgatgtaacc?tcaagagtta?cttacaagaa?tgtacctaac 420
tggcatagag?atctggtacg?agtgtgtgaa?aacatcccca?ttgtattgtg?tggcaacaaa 480
gtggatatta?aagacaggaa?agtgaaggca?aaatctattg?tcttccaccg?gaagaagaat 540
cttcagtact?atgacatttc?tgccaaaagt?aactacaact?ttgaaaagcc?tttcctctgg 600
cttgccagaa?agctcattgg?agatcctaac?ttggagttcg?ttgccatgcc?tgctcttgcc 660
ccacctgagg?tggtcatgga?cccagctttg?gcagcacagt?acgagcatga?tttagaggtt 720
gcccagacga?ccgctctccc?agatgaggat?gatgacctgt?gagaaagtga?agctggatgc 780
cctgcgtcag?aagtctagtt?ttatacgcaa?ctgtcctgtg?atgtcaagcg?gtgcagcgcg 840
tgtgccacct?tatttagcta?agcagatcgt?gtacttcatt?gggatgctga?aggagatgaa 900
tgggcttcga?gtgaatgtgg?cagttaaaca?caccttcatt?ttttggactt?gcatatttag 960
ctgtttggaa?cagagttgtt?tcttttccga?atttcaaaga?taagactgct?gcagtcccat 1020
cgcaatatcc?agtggggaaa?tcttgtttgt?tactgtcatt?cccattcttt?tcgttagaat 1080
cagaataaag?ttgtatttca?aataatctaa?aaaaaaaaaa?aaaaaaaaaa?aaaaaaaaaa 1140
aaaaaaaaaa?aaaaaaaaaa?aaaaaa 1166
<210>2
<211>216
<212>PRT
<213〉mice
<400>2
Met?Ala?Ala?Gln?Gly?Glu?Pro?Gln?Val?Gln?Phe?Lys?Leu?Val?Leu?Val
1 5 10 15
Gly?Asp?Gly?Gly?Thr?Gly?Lys?Thr?Thr?Phe?Val?Lys?Arg?His?Leu?Thr
20 25 30
Gly?Glu?Phe?Glu?Lys?Lys?Tyr?Val?Ala?Thr?Leu?Gly?Val?Glu?Val?His
35 40 45
Pro?Leu?Val?Phe?His?Thr?Asn?Arg?Gly?Pro?Ile?Lys?Phe?Asn?Val?Trp
50 55 60
Asp?Thr?Ala?Gly?Gln?Glu?Lys?Phe?Gly?Gly?Leu?Arg?Asp?Gly?Tyr?Tyr
65 70 75 80
Ile?Gln?Ala?Gln?Cys?Ala?Ile?Ile?Met?Phe?Asp?Val?Thr?Ser?Arg?Val
85 90 95
Thr?Tyr?Lys?Asn?Val?Pro?Asn?Trp?His?Arg?Asp?Leu?Val?Arg?Val?Cys
100 105 110
Glu?Asn?Ile?Pro?Ile?Val?Leu?Cys?Gly?Asn?Lys?Val?Asp?Ile?Lys?Asp
115 120 125
Arg?Lys?Val?Lys?Ala?Lys?Ser?Ile?Val?Phe?His?Arg?Lys?Lys?Asn?Leu
130 135 140
Gln?Tyr?Tyr?Asp?Ile?Ser?Ala?Lys?Ser?Asn?Tyr?Asn?Phe?Glu?Lys?Pro
145 150 155 160
Phe?Leu?Trp?Leu?Ala?Arg?Lys?Leu?Ile?Gly?Asp?Pro?Asn?Leu?Glu?Phe
165 170 175
Val?Ala?Met?Pro?Ala?Leu?Ala?Pro?Pro?Glu?Val?Val?Met?Asp?Pro?Ala
180 185 190
Leu?Ala?Ala?Gln?Tyr?Glu?His?Asp?Leu?Glu?Val?Ala?Gln?Thr?Thr?Ala
195 200 205
Leu?Pro?Asp?Glu?Asp?Asp?Asp?Leu
210 215
<210>3
<211>18
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: 5 ' primer
<400>3
tctaaaagct?gctgcagg 18
<210>4
<211>18
<212>DNA
<223〉artificial sequence
<220>
<223〉to the description of artificial sequence: 3 ' primer
<100>4
gtacacgatc?tgcttagc 18
<210>5
<211>23
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: 5 ' primer
<400>5
taatacgact?cactataggg?aga 23
<210>6
<211>30
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: 3 ' primer
<400>6
gaaattcaga?aaggaaacaa?ctctgttcca 30
<210>7
<211>20
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: 5 ' primer
<400>7
actataggga?gacccaagct 20
<210>8
<211>20
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: 3 ' primer
<400>8
agcagtcgtc?tgagcaacct 20

Claims (11)

1. low responsiveness lipopolysaccharide endotoxin response gene Lps dPreparing the purposes for the treatment of in the medicine that endotoxemia among the patient who needs is arranged, wherein said Lps dGene is different from corresponding Lps of the same race nThe gene part is that sudden change has taken place the 870th nucleotide of this Lps cDNA, and wherein said site numbering starts from translation initiation codon.
2. the purposes of claim 1, the wherein said T-C nucleotide that sports the 870th nucleotide of described Lps cDNA replaces.
3. the purposes of claim 1, wherein said Lps dGene exists with the form of viral vector.
4. the purposes of claim 3, wherein said viral vector is a retroviral vector.
5. the purposes of claim 3, wherein said viral vector is an adenovirus vector.
6. low responsiveness lipopolysaccharide endotoxin response gene Lps dIn preparation prevention purposes in the medicine of endotoxemia among the patient who needs, wherein said Lps are arranged dGene is different from corresponding Lps of the same race nThe gene part is that sudden change has taken place the 870th nucleotide of this Lps cDNA, and wherein said site numbering starts from translation initiation codon.
7. the purposes of claim 6, the wherein said T-C nucleotide that sports the 870th nucleotide of described Lps cDNA replaces.
8. the purposes of claim 6, wherein said Lps dGene exists with the form of viral vector.
9. the purposes of claim 8, wherein said viral vector is a retroviral vector.
10. the purposes of claim 8, wherein said viral vector is an adenovirus vector.
11. the purposes of claim 6, wherein the patient is the fire victim.
CNB998079499A 1998-04-27 1999-04-26 Method of treating endotoxemia Expired - Fee Related CN1213768C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8321098P 1998-04-27 1998-04-27
US60/083,210 1998-04-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2005100823601A Division CN1840659A (en) 1998-04-27 1999-04-26 Method of treating endotoxemia

Publications (2)

Publication Number Publication Date
CN1307487A CN1307487A (en) 2001-08-08
CN1213768C true CN1213768C (en) 2005-08-10

Family

ID=22176885

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2005100823601A Pending CN1840659A (en) 1998-04-27 1999-04-26 Method of treating endotoxemia
CNB998079499A Expired - Fee Related CN1213768C (en) 1998-04-27 1999-04-26 Method of treating endotoxemia
CNA2006101006405A Pending CN1990865A (en) 1998-04-27 1999-04-26 Method of treating endotoxemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2005100823601A Pending CN1840659A (en) 1998-04-27 1999-04-26 Method of treating endotoxemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006101006405A Pending CN1990865A (en) 1998-04-27 1999-04-26 Method of treating endotoxemia

Country Status (8)

Country Link
EP (1) EP1073471A4 (en)
JP (1) JP2002512984A (en)
KR (1) KR20010071185A (en)
CN (3) CN1840659A (en)
AU (1) AU768497B2 (en)
CA (1) CA2330033A1 (en)
HK (1) HK1039565B (en)
WO (1) WO1999055378A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322518A1 (en) * 2001-08-31 2003-03-18 Rosetta Inpharmactis Llc Methods for preparing nucleic acid samples
PT1984021T (en) * 2006-01-19 2016-11-02 Res Corp Tech Inc Viable non-toxic gram negative bacteria
CN101805392B (en) * 2007-07-10 2012-05-02 中国人民解放军第三军医大学野战外科研究所 Anti-inflammatory antibacterial polypeptide capable of blocking combination of LPS and MD2
EP3390644A1 (en) * 2015-12-15 2018-10-24 Genzyme Corporation Adeno-associated viral vectors for treating mucolipidosis type ii
CN114935654B (en) * 2022-05-26 2023-09-01 四川大学华西医院 Application of reagent or diagnostic device for detecting sample CD72 protein in preparation of reagent or kit for detecting sepsis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6594896A (en) * 1995-07-21 1997-02-18 Research Foundation Of State University Of New York, The Lipopolysaccharide endotoxin response gene and use thereof in screening agents for anti-endotoxemia activity

Also Published As

Publication number Publication date
AU3759499A (en) 1999-11-16
CA2330033A1 (en) 1999-11-04
CN1990865A (en) 2007-07-04
EP1073471A1 (en) 2001-02-07
CN1840659A (en) 2006-10-04
CN1307487A (en) 2001-08-08
JP2002512984A (en) 2002-05-08
KR20010071185A (en) 2001-07-28
WO1999055378A1 (en) 1999-11-04
HK1039565A1 (en) 2002-05-03
AU768497B2 (en) 2003-12-11
HK1039565B (en) 2005-10-21
EP1073471A4 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
CN1216064A (en) Synthetic HIV genes
CN1038306A (en) Recombinant retroviruses
CN1186501A (en) Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4
CN1434831A (en) Improvments in or relating to immune responses to HIV
CN1283121A (en) HIV-ITAT or derwatives thereof for prophylatic and therapeutic vacceination
CN1190991A (en) Human chemokine beta-11 and human chemokine alpha-1
CN1377275A (en) Peptides that block viral infectivity and methods of use thereof
CN1832963A (en) Specific inhibition of allograft rejection
Osterhaus et al. Isolation and partial characterization of a lentivirus from talapoin monkeys (Myopithecus talapoin)
CN1213768C (en) Method of treating endotoxemia
CN1148449C (en) Mutants of streptococcal toxin C and methods of use
US6331616B1 (en) Nucleic acids obtained from the envelope coding region of feline immunodeficiency virus molecular clone designated JSY3
US5413927A (en) Feline immunodeficiency virus isolate NCSU1Lb
CN1273191C (en) Method and composition for altering a B cell mediated pathology
EP1301637B1 (en) Dna vaccines encoding hiv accessory proteins
CN1150324C (en) Novel human lysozyme gene, its encoding polypeptide and the method preparing for them
CN1252257C (en) Human G-type lysozyme and its coding sequence, preparing process and application
JPH05502166A (en) Immunotherapeutic compositions for the treatment and prevention of AIDS, ARC and HIV infections
CN117903264A (en) Novel coronavirus SARS-CoV-2 HLA-A2 restriction epitope peptide and application
CN1253176A (en) Composition and method for protecting animals from diseases related with slow action virus
CN1219057C (en) Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB
CN1193981A (en) Human g-protein coupled receptor (HETGQ 23)
CN117659140A (en) Novel coronavirus HLA-A2 restriction epitope peptide and application thereof
CN1304410C (en) Tumor necrosis factor-Gamma
AU2004201044A1 (en) Method of treating endotoxemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee